Kalaris Therapeutics, Inc.
KLRS
$6.99
$0.294.33%
NASDAQ
| 12/31/2023 | |||||
|---|---|---|---|---|---|
| Net Income | -3.47M | ||||
| Total Depreciation and Amortization | -- | ||||
| Total Amortization of Deferred Charges | 6.00K | ||||
| Total Other Non-Cash Items | 130.00K | ||||
| Change in Net Operating Assets | -801.00K | ||||
| Cash from Operations | -4.14M | ||||
| Capital Expenditure | -- | ||||
| Sale of Property, Plant, and Equipment | -- | ||||
| Cash Acquisitions | -- | ||||
| Divestitures | -- | ||||
| Other Investing Activities | -- | ||||
| Cash from Investing | -- | ||||
| Total Debt Issued | 0.00 | ||||
| Total Debt Repaid | -- | ||||
| Issuance of Common Stock | -- | ||||
| Repurchase of Common Stock | -- | ||||
| Issuance of Preferred Stock | 6.74M | ||||
| Repurchase of Preferred Stock | -- | ||||
| Total Dividends Paid | -- | ||||
| Other Financing Activities | 117.00K | ||||
| Cash from Financing | 6.86M | ||||
| Foreign Exchange rate Adjustments | -- | ||||
| Miscellaneous Cash Flow Adjustments | -- | ||||
| Net Change in Cash | 2.72M | ||||